GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » EPS (Basic)

Scopus BioPharma (Scopus BioPharma) EPS (Basic) : $-0.32 (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma EPS (Basic)?

Scopus BioPharma's basic earnings per share (Basic EPS) for the three months ended in Jun. 2023 was $-0.07. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32.

Scopus BioPharma's EPS (Diluted) for the three months ended in Jun. 2023 was $-0.07. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.32.

Scopus BioPharma's EPS without NRI for the three months ended in Jun. 2023 was $-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.32.

During the past 3 years, the average EPS without NRI Growth Rate was -45.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Scopus BioPharma's highest 3-Year average EPS without NRI Growth Rate was -45.10% per year. The lowest was -229.40% per year. And the median was -137.25% per year.


Scopus BioPharma EPS (Basic) Historical Data

The historical data trend for Scopus BioPharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scopus BioPharma EPS (Basic) Chart

Scopus BioPharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS (Basic)
Get a 7-Day Free Trial -0.05 -0.18 -0.81 -1.56 -0.55

Scopus BioPharma Quarterly Data
Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.09 -0.08 -0.08 -0.07

Scopus BioPharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Scopus BioPharma's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.61-0)/21.094
=-0.55

Scopus BioPharma's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.617-0)/39.743
=-0.07

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scopus BioPharma  (OTCPK:SCPS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Scopus BioPharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Scopus BioPharma (Scopus BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein director, officer: Chairman 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager officer: See Remarks 1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson director, officer: Vice Chairman 71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Iv David Weild director 22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel director SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein director C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper director 7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka director, officer: President 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005

Scopus BioPharma (Scopus BioPharma) Headlines

From GuruFocus